U.S., March 25 -- ClinicalTrials.gov registry received information related to the study (NCT07491445) titled 'Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma' on March 10.
Brief Summary: The purpose of this study is to evaluate the safety and efficacy of an investigational RAS(ON) inhibitor administered as monotherapy or in combination with chemotherapy, compared with standard of care (SOC) chemotherapy alone.
Study Start Date: March 09
Study Type: INTERVENTIONAL
Condition:
Pancreatic Cancer
Pancreatic Cancer Metastatic
PDAC
PDAC - Pancreatic Ductal Adenocarcinoma
Pancreatic Ductal Adenocarcinoma (PDAC)
Pancreatic Adenocarcinoma Metastatic
Pancreatic Adenocarcin...